{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:07:26Z","timestamp":1767924446024,"version":"3.49.0"},"reference-count":37,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2004,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            AC98-6446 is a novel semisynthetic cyclic glycopeptide antibiotic related to the natural product mannopeptimycin \u03b1 (AC98-1). In the present study the activity of AC98-6446 was evaluated against a variety of recent clinical gram-positive pathogens including multiply resistant strains. AC98-6446 demonstrated similar potent activities against methicillin-susceptible and methicillin-resistant staphylococci and glycopeptide-intermediate staphylococcal isolates (MICs at which 90% of isolates are inhibited [MIC\n            <jats:sub>90<\/jats:sub>\n            s], 0.03 to 0.06 \u03bcg\/ml). AC98-6446 also demonstrated good activities against both vancomycin-resistant and -susceptible strains of enterococci (MIC\n            <jats:sub>90<\/jats:sub>\n            s, 0.12 and 0.25 \u03bcg\/ml, respectively) as well as against streptococcal strains (MIC\n            <jats:sub>90<\/jats:sub>\n            s, \u2264 0.008 to 0.03 \u03bcg\/ml). AC98-6446 demonstrated bactericidal activity in terms of the reduction in the viable counts (&gt;3 log\n            <jats:sub>10<\/jats:sub>\n            CFU\/ml) of staphylococcal and streptococcal isolates and a marked decrease in the viable counts of most enterococcal strains (from 0.2 to 2.5 log\n            <jats:sub>10<\/jats:sub>\n            CFU\/ml). Unlike vancomycin, which demonstrates time-dependent killing, AC98-6446 demonstrated concentration-dependent killing. The potent activity, novel structure, and bactericidal activity demonstrated by AC98-6446 make it an attractive candidate for further development.\n          <\/jats:p>","DOI":"10.1128\/aac.48.3.739-746.2004","type":"journal-article","created":{"date-parts":[[2004,2,24]],"date-time":"2004-02-24T17:53:08Z","timestamp":1077645188000},"page":"739-746","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":54,"title":["Comparative In Vitro Activities of AC98-6446, a Novel Semisynthetic Glycopeptide Derivative of the Natural Product Mannopeptimycin \u03b1, and Other Antimicrobial Agents against Gram-Positive Clinical Isolates"],"prefix":"10.1128","volume":"48","author":[{"given":"Peter J.","family":"Petersen","sequence":"first","affiliation":[{"name":"Infectious Disease Research, Microbiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. Z.","family":"Wang","sequence":"additional","affiliation":[{"name":"Chemical and Screening Sciences, Medicinal Chemistry, Wyeth Research, Pearl River, New York 10965"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell G.","family":"Dushin","sequence":"additional","affiliation":[{"name":"Chemical and Screening Sciences, Medicinal Chemistry, Wyeth Research, Pearl River, New York 10965"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia A.","family":"Bradford","sequence":"additional","affiliation":[{"name":"Infectious Disease Research, Microbiology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/jac\/43.5.689","volume":"43","year":"1999","unstructured":"Andrews, J., J. Ashby, G. Jevons, N. Lines, and R. Wise. 1999. Antimicrobial resistance in gram-positive pathogens isolated in the UK between October 1996 and January 1997. J. Antimicrob. Chemother.43:689-698.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_3_2","first-page":"565","volume":"51","year":"2002","unstructured":"Centers for Disease Control and Prevention. 2002. Staphylococcus aureus resistant to vancomycin, United States, 2002. Morbid. Mortal. Wkly. Rep.51:565-567.","journal-title":"Morbid. Mortal. Wkly. Rep."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1086\/313597","volume":"30","year":"2000","unstructured":"Chien, J. W., M. L. Kucia, and R. A. Salata. 2000. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin. Infect. Dis.30:146-151.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1369-5274(99)00002-8"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1128(199911)19:6<497::AID-MED3>3.0.CO;2-R"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.23.4.614"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200059010-00002"},{"key":"e_1_3_2_9_2","first-page":"534","volume":"37","year":"1989","unstructured":"Facklam, R., and D. Collins. 1989. Identification of Enterococcus species isolated from human infections by a conventional test scheme. J. Clin. Microbiol.37:534-541.","journal-title":"J. Clin. Microbiol."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(99)00092-9"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.9.2452"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04376-2"},{"key":"e_1_3_2_13_2","first-page":"1291","volume":"285","year":"2001","unstructured":"Green, S. L., L. C. Maddox, and E. D. Huttenbach. 2001. Linezolid and reversible myelosuppression. JAMA285:1291.","journal-title":"JAMA"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jac\/41.2.273","volume":"41","year":"1998","unstructured":"Harland, S., S. E. Tebbs, and T. S. Elliott. 1998. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin. J. Antimicrob. Chemother.41:273-276.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja020257s"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0732-8893(98)00108-4","volume":"33","year":"1999","unstructured":"Jones, R. N., D. E. Low, and M. A. Pfaller. 1999. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn. Microbiol. Infect. Dis.33:101-112.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(97)00115-6"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.6.1075"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958060-00008"},{"key":"e_1_3_2_20_2","first-page":"1541","volume":"48","year":"1998","unstructured":"Lucet, J. C. 1998. Control of multiple-resistant bacteria. Rev. Praticien.48:1541-1546.","journal-title":"Rev. Praticien."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.4.930"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(97)00212-5"},{"key":"e_1_3_2_23_2","unstructured":"National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guidelines M26-A vol. 19. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_24_2","unstructured":"National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A5 vol. 20. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_25_2","first-page":"173","volume":"1","year":"2000","unstructured":"Pavan, B. 2000. Synercid. Curr. Opin. Investig. Drugs1:173-180.","journal-title":"Drugs"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2595-2601.2002"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.4.738"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00149-7"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(97)00159-4"},{"key":"e_1_3_2_30_2","first-page":"729","volume":"48","year":"2004","unstructured":"Ruzin, A., G. Singh, A. Severin, Y. Yang, R. G. Dushin, A. G. Sutherland, A. Minnick, M. Greenstein, M. K. May, D. M. Shlaes, and P. A. Bradford. 2004. Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant gram-positive bacteria. Antimicrob. Agents Chemother.48:729-739.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.1.62-69.2003"},{"key":"e_1_3_2_32_2","unstructured":"Stratton C. W. and R. C. Cooksey. 1991. Susceptibility tests: special tests p. 1153-1165. In A. Balows W. J. Hausler Jr. K. L. Herrmann H. D. Isenberg and H. J. Shadomy (ed.) Manual of clinical microbiology 5th ed. American Society for Microbiology Washington D.C."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(99)00216-4"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.8.8.1223"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-6701(99)90060-9"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.11.2270"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/clind\/24.4.584"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.5.1370-1374.2000"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.3.739-746.2004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.3.739-746.2004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:15:06Z","timestamp":1645467306000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.48.3.739-746.2004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["10.1128\/AAC.48.3.739-746.2004"],"URL":"https:\/\/doi.org\/10.1128\/aac.48.3.739-746.2004","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3]]},"assertion":[{"value":"2003-08-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-11-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}